Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 885

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1

Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595

Untersuchung der Effekte des GLP-1 Systems auf Komponenten des Metabolischen Syndrom in vivo

Piotrowski, K. (2013) · doi:10.5282/edoc.15458

Effect of endogenous and exogenous ghrelin on gastrointestinal function in rat and human

Falkén, Y. (2013) · Figshare

Management Strategies for Type 2 Diabetes: Focus on Vildagliptin

Cope, N. M. A. D. (2010) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s3537

Exenatide: A Novel Therapeutic Approach for Type 2 Diabetes Mellitus

McCord, A. D. (2005) · Journal of Pharmacy Technology · doi:10.1177/875512250502100402

Adolescent type 1 diabetes : Eating and gastrointestinal function

Lodefalk, M. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)

A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT

Andréasson, S. (2015) · Epsilon Archive for Student Projects (University of Southampton)

Inkretinmimetika und Inkretinverstärker

Nauck, M. A. (2007) · Der Diabetologe · doi:10.1007/s11428-007-0142-2

GABA A receptor-mediated synaptic and tonic currents in rat

Korol, S. V., Jin, Z., Babateen, O., & Birnir, B. (2014)

NUEVOS FÁRMACOS EN DIABETES TIPO 2

Carlos Zavala, U. (2008) · Revista Médica Clínica Las Condes

ENTERO-OMENTECTOMIA ADAPTATIVA COMO TRATAMENTO AUXILIAR DO DIABETES MELLITUS TIPO 2

Milléo, F. Q. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

POUR LE DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

Sabatier, P., Médecine, F. D., Clinique, M. S., & Bally, É. (2013)

Development of new incretin drugs: Promising therapies Development of new incretin drugs: Promising therapies Development of new incretin drugs: Promising therapies Development of new incretin drugs: Promising therapies Development of new incretin drugs: Promising therapies

Kaur, K. (2006)

Whey protein

Ney, D. M., & Boehler, C. J. (2011) · Nutrafoods · doi:10.1007/bf03223384

Über die Bedeutung der Zugabe von humanem Serum-Albumin zu exogenen GLP-1-Infusionen am Beispiel der Antagonisierbarkeit des GLP-1 [7-36-Amid]-Einflusses auf die erste Phase der Insulin-Sekretion nach intravenöser Glukosegabe durch den GLP-1-Rezeptor-Antagonisten Exendin [9-39] bei gesunden Menschen

Köthe, L. (2011) · doi:10.53846/goediss-1062

Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients

Røge, R. M. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)

Marine invertebrate and bacterial extract library screens for novel modulators of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors

Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089

GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator

Babateen, O. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)

Exenatide as a novel treatment for Parkinson's Disease

Avilés-Olmos, I. (2013) · UCL Discovery (University College London)

Incretin hormones as a target for therapy

Holst, J. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_2

Non‐Insulin Parenteral Therapies

Vilsbøll, T., Christensen, M., Jorsal, T., & Knop, F. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch32

The role of gut hormones on food intake and carbohydrate tolerance

Tharakan, G. (2016) · Spiral (Imperial College London) · doi:10.25560/41846

The Role of Efferent Cholinergic Transmission for the Insulinotropic and

Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Tina, T., Knop, F. K., & Holst, J. J. (2015)

The Effect of Micro Element Levels in Drinking Water on Adolescent Body Composition

Çetin, İ., Nazik, A., Nalbantçılar, M. T., & Tosun, K. (2017) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2017.13471

Obesity induced dysfunction of gastric vagal afferent signalling.

Kentish, S. J. (2013) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)

Avaliação do metabolismo glicêmico e perfil entero-hormonal no pós-operatório precose em pacientes abesos graves diabéticos submetidos à gastroplastia em Y de Roux.Comparação da oferta alimentar por via oral e por gastrostomia

Fernandes, G. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2017.tde-29112017-091214

Η συσχέτιση του πολυμορφισμού του γονιδίου GLUT1 στη διαβητική αμφιβληστροειδοπάθεια και νεφροπάθεια στον σακχαρώδη διαβήτη τύπου ΙΙ

Φωτιάδου, Α. (2018) · doi:10.12681/eadd/42593

The role of physiological elevations of glucagon-like peptide-one in glucose regulation in the dog in vivo

Johnson, K. M. S. (2008)

Molecular modelling as a tool for designing dipeptidylpeptidase-4 inhibitors

Mehanna, A., & Hendawy, M. (2021) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2021.10.00363

Applications in nutrition: clinical nutrition

Liu, W., Chen, L., Wei, Y., Li, G., Liu, Y., Wang, Y.-C., Wang, Y., Qin, X., Cui, X., Gu, R., et al. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821389-6.00019-4

Incretin Mimetics in the Treatment of Type 2 Diabetes Mellitus

Holst, J. J. (2006) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2006.00.01.1g · Cited by 1

GLP-1

Williams, J. A. (2021) · doi:10.3998/panc.2021.06

Faculty Opinions recommendation of Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.

Hert, S. G. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734529586.793559018

Secretion and Impact of Gut Hormones in Obesity and Diabetes

Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9

Non‐insulin Parenteral Therapies

Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36

Additional file 1 of Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery

Kweon, S., Lee, J. H., Yang, S.-B., Park, S. J., Subedi, L., Shim, J., Cho, S., Choi, J. U., Byun, Y., Park, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24078417

Ectopic fat deposition in intestinal wall caused the increase of L cell pyroptosis mainly through local hypoxia

Liu, Y., Wu, H., Ma, Q., Lu, Z., Zhao, P., Li, X., Li, M., & Wen, J. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.12.002

Glucagon-like Peptides and Insulin Sensitivity

Holst, J. J., & Knop, F. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_13

Bibliography

(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5

Inflammation intestinale et diabète de type 2 : effet du Resveratrol

Dao, T. M. A. (2011) · theses.fr (ABES) · doi:10.70675/ba3c8576z889ez4199zb7d6z98de312b9efb

Regenerative and Hepatotropic Properties of GLP-1 and GLP-2: Mechanistic Insights and Implications for Post-Hepatectomy Liver Regeneration: A Narrative Review

Mahamid, A., Shtaya, A. A., Mouch, S. A., Haddad, R., Zeina, A., & Baker, F. A. (2026) · Livers · doi:10.3390/livers6030036

A multi-scale quantitative systems pharmacology model of the Pharmaco-Nutritional Kinetic Paradox: GLP-1 receptor agonists, colonic fibre fermentation and endogenous GLP-1 signallingPreprint

Choudhary, A. K., & Sahu, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10780569/v1

Structural Overview of GLP-1 Analogs

van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037

From Food Structure to L-Cell Exposure: How Processing and Digestion Shape Endogenous GLP-1 Responses

Šantić, R., Kumrić, M., Kurir, T. T., Rušić, D., & Božić, J. (2026) · Molecules · doi:10.3390/molecules31193375

More than just adipose: the impact of GLP1RA on lean tissue

Julien, M., Jeromson, S., & Wright, D. C. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.90062.2026

BindingDB Entry 50038978: Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

BindingDB (2012) · UC San Diego · doi:10.7270/q2vh5prk

BindingDB Entry 50038438: Small-molecule agonists for the glucagon-like peptide 1 receptor.

BindingDB (2012) · UC San Diego · doi:10.7270/q21r6rd8

BindingDB Entry 50048179: Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.

BindingDB (2018) · UC San Diego · doi:10.7270/q2fj2jrd

BindingDB Entry 50025969: Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.

BindingDB (2010) · UC San Diego · doi:10.7270/q2736qpr

BindingDB Entry 50040257: Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

BindingDB (2013) · UC San Diego · doi:10.7270/q2jq123c

BindingDB Entry 50045129: Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.

BindingDB (2016) · UC San Diego · doi:10.7270/q2v69m60

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects

Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 75

Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus

Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Fanelli, A., Messeri, G., & Rotella, C. M. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00367.x · Cited by 106

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251

Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes

Gutniak, M., Svartberg, J. B., Hellström, P. M., Holst, J. J., Adner, N., & Åhrén, B. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00862.x · Cited by 27

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369